The absence of evidence for blood-based EAA measures as biomarkers of AD conversion is consistent with several recent studies on pre-symptomatic dementia cases [77, 78], MCI, or manifest dementia cases [79], as well as observed null associations with Aβ, p-tau, or t-tau status in cerebrospinal fluid [36]. The gene discussed is MAPT; the disease is dementia.